#Arthritis Medication

[dumbasnothing]

A few highlights from when me and my friends made a bunch of memes as if we were old folks who don’t understand what memes are

[pharmanucleus1]

Global Osteoarthritis Market: Trends, Treatment, and Projections 2030

Report Summary 

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Click here for full report:

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

Click here for free sample request:

Viscosupplementation segment industry accounted for the highest market share in 2021 

The rising prevalence of knee osteoarthritis is the key driver of this market's expansion. By injecting synovial fluid into the afflicted joints, which increases lubrication, viscosupplementation greatly lowers osteoarthritis discomfort. Furthermore, the market for viscosupplementation agents is expected to grow considerably over the forecast period due to the discovery of novel viscosupplementation agents and government efforts to boost research in the healthcare sector. 

Hospital Pharmacies are expected to hold the significant revenue share 

Hospital pharmacies retained the largest share of this market due to the large number of patients seeking treatment for osteoarthritis in hospitals and the vast assortment of osteoarthritis drugs available in these pharmacies. Another important advantage is the ease with which hospital pharmacy purchases may be reimbursed. 

The demand in North America is expected to witness significant growth 

A rise in the frequency of chronic diseases, an increase in the number of elderly people, and changes in people's lifestyles all contribute to the anticipation of market expansion in North America. As a result, the region is incorporating an increasing number of treatments and drugs. When compared to Canada and Mexico, the United States will command a substantial share of the North American market for osteoarthritis therapies. 

According to the CDC, osteoarthritis (OA), the most common kind of arthritis, is a severe chronic illness that affects 32.5 million individuals in the United States. OA is associated with ageing and is more common in those with other chronic conditions such as obesity, diabetes, and heart disease. However, 18.7 million people with OA, or more than half of them, are of working age (18 to 64 years). 

Furthermore, the availability of better treatment alternatives, government reimbursement guidelines, increased research and development activities in the creation of novel medicines, and the introduction of new therapies in the North American region are all expected to support market expansion in the region. 

Europe controlled the market for osteoarthritis therapies. The increased incidence of osteoarthritis, the ageing population, rising obesity rates in several European countries, and the growing number of sports- and accident-related injuries all contribute to this sector's large market share. 

[bookdoctorconsultationonline]

Overview & Types Of Medicine & Antibiotics For Arthritis at Livlong

Explore the different arthritis medicine like over-the-counter and prescription drugs & other effective medicine for arthritis. Visit Livlong for more information on arthritis medications & antibiotics!

[allhealthneedsdoctorconsultation]

Overview & Types Of Medicine & Antibiotics For Arthritis at Livlong

Explore the different arthritis medicine like over-the-counter and prescription drugs & other effective medicine for arthritis. Visit Livlong for more information on arthritis medications & antibiotics!

[pangur-and-grim]

today we had bloodwork for Belphie, and Solensia for Pangur! they are reluctant vet buddies

[reasonsforhope]

"A team at Northwestern University has come up with the term “dancing molecules” to describe an invention of synthetic nanofibers which they say have the potential to quicken the regeneration of cartilage damage beyond what our body is capable of.

The moniker was coined back in November 2021, when the same team introduced an injection of these molecules to repair tissues and reverse paralysis after severe spinal cord injuries in mice.

Now they’ve applied the same therapeutic strategy to damaged human cartilage cells. In a new study, published in the Journal of the American Chemical Society, the treatment activated the gene expression necessary to regenerate cartilage within just four hours.

And, after only three days, the human cells produced protein components needed for cartilage regeneration, something humans can’t do in adulthood.

The conceptual mechanisms of the dancing molecules work through cellular receptors located on the exterior of the cell membrane. These receptors are the gateways for thousands of compounds that run a myriad of processes in biology, but they exist in dense crowds constantly moving about on the cell membrane.

The dancing molecules quickly form synthetic nanofibers that move according to their chemical structure. They mimic the extracellular matrix of the surrounding tissue, and by ‘dancing’ these fibers can keep up with the movement of the cell receptors. By adding biological signaling receptors, the whole assemblage can functionally move and communicate with cells like natural biology.

“Cellular receptors constantly move around,” said Northwestern Professor of Materials Sciences Samuel Stupp, who led the study. “By making our molecules move, ‘dance’ or even leap temporarily out of these structures, known as supramolecular polymers, they are able to connect more effectively with receptors.”

The target of their work is the nearly 530 million people around the globe living with osteoarthritis, a degenerative disease in which tissues in joints break down over time, resulting in one of the most common forms of morbidity and disability.

“Current treatments aim to slow disease progression or postpone inevitable joint replacement,” Stupp said. “There are no regenerative options because humans do not have an inherent capacity to regenerate cartilage in adulthood.”

In the new study, Stupp and his team looked to the receptors for a specific protein critical for cartilage formation and maintenance. To target this receptor, the team developed a new circular peptide that mimics the bioactive signal of the protein, which is called transforming growth factor beta-1 (TGFb-1).

Northwestern U. Press then reported that the researchers incorporated this peptide into two different molecules that interact to form supramolecular polymers in water, each with the same ability to mimic TGFb-1...

“With the success of the study in human cartilage cells, we predict that cartilage regeneration will be greatly enhanced when used in highly translational pre-clinical models,” Stupp said. “It should develop into a novel bioactive material for regeneration of cartilage tissue in joints.”

“We are beginning to see the tremendous breadth of conditions that this fundamental discovery on ‘dancing molecules’ could apply to,” Stupp said. “Controlling supramolecular motion through chemical design appears to be a powerful tool to increase efficacy for a range of regenerative therapies.”"

-via Good News Network, August 5, 2024

[burythecarnival]

i am such a stressed out little ghost. the last week has cast a dark energy on me & i am so fucking exhausted. recovering from my biopsy, pain-somia, medical horror nightmares, juggling getting my prescriptions, feeling just...really disheartened. now on top of everything, i need to take boba fett, my calico angel, to the vet tomorrow. she has been my little best friend for fourteen years & i know something is wrong.

i have also felt so fucking badly about myself & it is getting v hard to practice kindness to myself. i am on the verge of building a pillow fort to hide & cry in.

any help is immensely appreciated 🖤 i know money is tight for plenty of you; please do not apologize if you cannot donate! i appreciate you & just the fact that you genuinely care. i feel safe here.

luv, cuddles & cauldron bubbles, the ghost queen 👻

✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨✨

cashapp: $dryboneslive / venmo: dryboneslive

paypal: message me for email

[ineffectualdemon]

Me: *can't stand for longer then 20 seconds unsupported without feeling like in going to throw up from pain, can barely walk, live at a 7 on the pain scale, literally cannot get out of bed most days, had to take a nap today because showering was too much even though I have a stool to help me. Has been given disability benefits from the government on the first attempt and also has been deemed low capacity for work and work like activity by the government*

Also me: I dunno. I feel bad taking a space at the hydrotherapy pool. That it should go to people who are properly disabled

-

WHY AM I LIKE THIS

[talkethtothehandeth]

Mayo Clinic attending and vascular surgeon: there’s something up with your arteries, they’re narrowed and you have some stenosis

Local doctors: there’s nothing wrong with you, you’re too young to have treatment and you might actually be insane have you considered that? also go fuck yourself dumb whore

[sodaacrush]

URGENT!! PLEASE READ/SHARE 🚑‼️📢

My parents have started a GoFundMe for my mothers medical expenses because insurance doesn't cover all of her medicines, supplies to wrap her deep wounds, or hospital bills anymore. My mother is disabled and requires constant medical care. I'm begging you to spread this as far as you can!! Even just sharing the link helps! https://www.gofundme.com/f/4hu3ma-uncovered-medical-costs?utm_campaign=p_lico+share-sheet&utm_medium=copy_link&utm_source=customer

[anexperimentallife]

Again, if I haven't responded to you, I apologize. Please keep in mind that I am OLD, that I am recovering from Dengue (which my brother-in-law calls my "reggae fever" lol), am getting over a brutal assault that permanently damaged both of my eyes, that I have brain fog and other challenges from long Covid, a TBI, and ADHD, am autistic, and have chronic pain from two spine injuries, in addition to severe joint pain from osteo- and rheumatoid arthritis AND various joint injuries, including the long-term effects of how they attempted to correct a birth defect in my legs when I was a child.

I'm ALSO trying to finish writing this damn book when I have spare time and the ability to type, so that I can try to get my writing career (which was was barely beginning when it was interrupted by the deaths of my sons) back on track.

So yeah. It's not you; I've just got a lot going on, and for the next few weeks I'll likely just be on here long enough to fill my queue and maybe type a quick update or shitpost, or maybe share a pic of some kind. When I have spoons and energy, my first priorities are being as good a dad to Baby El, and as good a husband to @thesurestthing as I can be. Those two things (plus recovery) take up pretty much ALL my spoons lately.

[critter-creature-or-beast]

Of course you know all this week is the anniversary event, Cambrian Week. But today is the actual one year anniversary of the blog 🥳

[pharmanucleus1]

Global Osteoarthritis Market, Forecast to 2030

In 2023, the worldwide osteoarthritis market was valued at USD 7.40 billion and is predicted to increase at an 8.5% CAGR during the forecast period 2023-2030. Both the introduction of analgesic drugs and the development of imaging diagnostics based on radiographic characteristics are stimulating market growth. Increased expenditure on healthcare infrastructure and expanding investments in research and development (R&D) efforts to bring novel diagnostics and biomarkers are also driving the market. 

Osteoarthritis (OA) is a group of disorders that affect the joints of the knees, hips, fingers, foot, back, shoulders, and neck. It is distinguished by the gradual degeneration of the cartilage in these joints. Stiffness, edoema, discomfort, persistent pain, loss of flexibility, a grating sensation, bone spurs, and sleep interruptions are all common symptoms of OA. 

Click here for view full report:

Medical examination, X-rays, arthroscopy, joint fluid analysis, lab testing, and magnetic resonance imaging (MRI) scans can all be used to diagnose it. Depending on the outcomes, different medications and surgical techniques are prescribed to treat the disease's signs and symptoms. There are presently alternative medicines, physical therapy, and supporting devices on the market to relieve pain and improve joint function. 

Sedentary lifestyles, poor eating habits, and increasing weight and blood sugar levels make people more susceptible to develop OA. This is one of the primary driving drivers for market development, combined with an ageing population that is more susceptible to such disorders. Furthermore, the ease of access to MRI scans is a key growth-promoting factor. 

Click here for Request free sample:

The COVID-19 outbreak is predicted to have only a minimal influence on the osteoarthritis therapy industry. Corticosteroids are being used less often in many medicine types. Although there is no evidence that corticosteroid injections significantly increase the risk of infection, the immune system may be less active for a few weeks following surgery. 

Even though the risk is extremely minimal, it should be taken into account before starting with the procedure. It should be noted that the World Health Organisation cautioned against the use of systemic corticosteroids in one of its guidelines for treating severe acute respiratory infections caused by coronavirus. 

Industry Dynamics 

Growth Drivers:  

Increased government investment on cell-based research, as well as the increasing use of opioids, are driving market expansion. Topical, oral, and analgesic medications are commonly used to treat osteoarthritis pain. Even if alternatives such as orthopaedic braces are used as part of a noninvasive approach to pain therapy, the adoption of pain pills for the disease is substantial due to the ease of administration and the cost of pain medications. Oral analgesics such as acetaminophen, NSAIDs, intra-articular medicines, and nutraceuticals are all common pain relievers. 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

The use of biomarkers to identify individuals who are most likely to respond to specific medical therapies may increase treatment response rates and reduce the risk of exposing patients to medicines that are either unlikely to be effective or may cause harmful side effects from their treatment. Using a mix of unique biomarkers and baseline clinical parameters such as age and gender might be beneficial. 

Report Segmentation 

The market is primarily segmented based on treatment type, disease type, distribution channel, route of administration, and region. 

Knee Osteoarthritis segment is expected to witness fastest growth 

Personalised OA medications have also been proposed, which would represent a considerable advance in the diagnosis, therapy, and monitoring of disease severity in osteoarthritis patients. Simple measurement, appropriate levels of sensitivity and specificity, and test procedures available to and interpretable by clinicians are critical qualities of indicators of therapeutic relevance for a personalised approach to OA therapy. 

Click here for view full report:

Furthermore, increased FDA approvals for the treatment of Knee OA are driving sector growth throughout the projection period. For example, Novartis announced in September 2021 that LNA043 had been granted fast-track designation by the US Food and Drug Administration (FDA) for knee osteoarthritis rehabilitation. 

Drugs targeted to treat severe diseases and address unmet medical needs can be created more swiftly and evaluated more quickly. LNA043, a possibly first-in-class disease-modifying treatment for osteoarthritis, is being developed. As a result, growing approvals for the treatment of knee OA drive market development throughout the projection period. 

[littlequeen7]

As someone who has been medically gaslit and ignored for my entire life...

And with these last couple months being some of my worst for pain ever...

I was just diagnosed with POTS and fibromyalgia. They're putting me on a medication to manage my pain. They're going to try to do nerve blockers to mitigate some of the pain in my neck and head. They're ordering x-rays and blood tests. They're going to refer me to a rheumatologist.

I want to cry. Is this what it's like for other people, seeking medical treatment? Having someone who actually listens to you when you tell them about your debilitating disabilities and actively tries to help you figure things out and stop the pain?

I am so hopeful for the future but simultaneously so angry and disappointed in every medical provider who has failed me in the past. Getting actual medical treatment should not be an abnormal, shocking and life changing thing.

[nondivisable]

sometimes being chronically ill as a teenager is actually ridiculously funny because my blood tests can show ridiculous numbers regarding antibodies and I can literally have fluid in my joints (arthritis) and doctors will still only tell me to go to physical therapy

(shoutout to my one cool doctor who's advocating for me and completely enraged about the fact that no one told I had ra)

[indagold-orchid]

Don't tend to post about my trillions of health problems but anyone got psoriatic/rheumatoid arthritis and dealt with biologics? My doc is probably gonna put me on those since my medication doesn't seem to work and that stuff will probably bankrupt me.

Isn't there cheaper options? I don't want to spend thousands a year on medication. Prices can be from 2000 - 20,000 a year and that's scaring me.